ZA200200738B - Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity. - Google Patents

Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity.

Info

Publication number: ZA200200738B
Authority: ZA; South Africa
Prior art keywords: obesity; manufacture; treatment; monoamine oxidase; oxidase inhibitors
Prior art date: 1999-08-16

Application number

ZA200200738A

Other languages

English (en)

Inventor

Pierre Rosenzweig

Original Assignee

Sanofi Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-16

Filing date

2002-01-28

Publication date

2003-03-26

2002-01-28 Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo

2003-03-26 Publication of ZA200200738B publication Critical patent/ZA200200738B/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Child & Adolescent Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200200738A 1999-08-16 2002-01-28 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity. ZA200200738B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99116026A EP1078632A1 (en)	1999-08-16	1999-08-16	Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity

Publications (1)

Publication Number	Publication Date
ZA200200738B true ZA200200738B (en)	2003-03-26

Family

ID=8238777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200200738A ZA200200738B (en)	1999-08-16	2002-01-28	Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity.

Country Status (22)

Country	Link
EP (2)	EP1078632A1 (is)
JP (1)	JP2003506485A (is)
KR (1)	KR20020025971A (is)
CN (1)	CN1370067A (is)
AR (1)	AR025244A1 (is)
AU (1)	AU6441900A (is)
BR (1)	BR0013282A (is)
CA (1)	CA2377133A1 (is)
CZ (1)	CZ2002554A3 (is)
EA (1)	EA200200117A1 (is)
EE (1)	EE200200062A (is)
HK (1)	HK1046104A1 (is)
HU (1)	HUP0203601A2 (is)
IL (1)	IL147790A0 (is)
IS (1)	IS6251A (is)
MX (1)	MXPA02001649A (is)
NO (1)	NO20020770L (is)
PL (1)	PL364865A1 (is)
SK (1)	SK2162002A3 (is)
TR (1)	TR200200376T2 (is)
WO (1)	WO2001012176A2 (is)
ZA (1)	ZA200200738B (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1307182B1 (fr) *	2000-08-01	2005-03-30	Sanofi-Aventis	Composition pharmaceutique pour administration transdermique de befloxatone
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da)	2001-01-26	2006-10-23	Schering Corp	Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
DE10142660A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
AU2002331064B2 (en)	2001-08-10	2007-08-23	Palatin Technologies, Inc.	Peptidomimetics of biologically active metallopeptides
US7456184B2 (en)	2003-05-01	2008-11-25	Palatin Technologies Inc.	Melanocortin receptor-specific compounds
US7354923B2 (en)	2001-08-10	2008-04-08	Palatin Technologies, Inc.	Piperazine melanocortin-specific compounds
DE10142659A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142667B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE10142722A1 (de)	2001-08-31	2003-03-27	Aventis Pharma Deutschland GmbH, 65929 Frankfurt	C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10142668A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142662B4 (de)	2001-08-31	2004-07-08	Aventis Pharma Deutschland Gmbh	Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142666A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142663B4 (de)	2001-08-31	2004-08-19	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-ol-Systeme
DE10142665B4 (de)	2001-08-31	2004-05-06	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-one und ihre Derivate
DE10142661B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2487849A1 (en)	2002-07-18	2004-01-29	Cytos Biotechnology Ag	Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en)	2003-03-07	2011-07-05	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
DE10342672A1 (de) *	2003-09-16	2005-04-21	Bayer Chemicals Ag	Chirale Phosphane zur Verwendung in asymmetrischen Synthesen
CN101300006B (zh)	2005-06-02	2012-07-25	叶林发现公司	用于治疗肥胖的mao-b抑制剂
WO2006138475A2 (en) *	2005-06-16	2006-12-28	Jenrin Discovery	Mao-b inhibitors useful for treating obesity
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
ATE554085T1 (de)	2006-11-30	2012-05-15	Probiodrug Ag	Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja)	2007-03-01	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en)	2007-04-18	2014-12-24	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009070533A1 (en) *	2007-11-29	2009-06-04	Complegen, Inc.	Methods of inhibiting steroyl coa desaturase
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP5934645B2 (ja)	2009-09-11	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja)	2010-03-03	2016-11-16	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤
NZ602312A (en)	2010-03-10	2014-02-28	Probiodrug Ag	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
US9133123B2 (en)	2010-04-23	2015-09-15	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP2686313B1 (en)	2011-03-16	2016-02-03	Probiodrug AG	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN102267990B (zh) *	2011-06-03	2013-11-13	浙江工业大学	一种2,3-二氢苯并呋喃类衍生物及其制备与应用
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt)	2013-06-05	2017-08-29	Synergy Pharmaceuticals Inc	Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
ES2812698T3 (es)	2017-09-29	2021-03-18	Probiodrug Ag	Inhibidores de glutaminil ciclasa
CN110511208B (zh) *	2019-08-02	2020-08-25	浙江工业大学	N-2-吡啶基-2,3-二叠氮吲哚啉类化合物及其制备与应用
KR20230075912A (ko)	2021-11-23	2023-05-31	서제표	접이식 안경

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3153092A (en) *	1961-07-17	1964-10-13	Smith Kline French Lab	1-methyl-2-phenylcyclopropylamine derivatives
US3466236A (en) *	1965-11-09	1969-09-09	Eastman Kodak Co	Irradiation of aminocyclobutanones
AU5550780A (en) *	1979-04-26	1980-10-30	Merrell Toraude Et Compagnie	Alpha-halomethyl amines
FR2724171B1 (fr) *	1994-09-05	1997-01-03	Synthelabo	Derives de 3,3a,4,5-tetrahydro-1h-oxazolo(3,4-a)quinolein-1-one, leur preparation et leur application en therapeutique
KR100457502B1 (ko) *	1995-06-02	2005-09-05	사노피-신델라보	옥사졸리디논유도체,그것의제법및치료학적사용
US5969146A (en) *	1995-10-11	1999-10-19	Synthelabo	Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
US5955471A (en) *	1998-01-13	1999-09-21	Sk Corporation	Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
US6303617B1 (en) *	1998-05-04	2001-10-16	Neotherapeutics, Inc.	Serotonin-like 9-substituted hypoxanthine and methods of use
AU5330599A (en) *	1998-07-31	2000-02-21	Vela Pharmaceuticals Inc.	Methods and compositions for treating and preventing certain psychiatric and medical disorders using moclobemide

1999
- 1999-08-16 EP EP99116026A patent/EP1078632A1/en not_active Withdrawn
2000
- 2000-08-08 JP JP2001516522A patent/JP2003506485A/ja not_active Withdrawn
- 2000-08-08 HK HK02107811.0A patent/HK1046104A1/zh unknown
- 2000-08-08 EP EP00951508A patent/EP1210080A2/en not_active Withdrawn
- 2000-08-08 KR KR1020027001959A patent/KR20020025971A/ko not_active Withdrawn
- 2000-08-08 BR BR0013282-9A patent/BR0013282A/pt not_active Application Discontinuation
- 2000-08-08 MX MXPA02001649A patent/MXPA02001649A/es unknown
- 2000-08-08 AU AU64419/00A patent/AU6441900A/en not_active Abandoned
- 2000-08-08 IL IL14779000A patent/IL147790A0/xx unknown
- 2000-08-08 PL PL00364865A patent/PL364865A1/xx not_active Application Discontinuation
- 2000-08-08 CZ CZ2002554A patent/CZ2002554A3/cs unknown
- 2000-08-08 WO PCT/EP2000/007917 patent/WO2001012176A2/en not_active Ceased
- 2000-08-08 EE EEP200200062A patent/EE200200062A/xx unknown
- 2000-08-08 EA EA200200117A patent/EA200200117A1/ru unknown
- 2000-08-08 TR TR2002/00376T patent/TR200200376T2/xx unknown
- 2000-08-08 SK SK216-2002A patent/SK2162002A3/sk unknown
- 2000-08-08 HU HU0203601A patent/HUP0203601A2/hu unknown
- 2000-08-08 CA CA002377133A patent/CA2377133A1/en not_active Abandoned
- 2000-08-08 CN CN00811699A patent/CN1370067A/zh active Pending
- 2000-08-15 AR ARP000104209A patent/AR025244A1/es unknown
2002
- 2002-01-25 IS IS6251A patent/IS6251A/is unknown
- 2002-01-28 ZA ZA200200738A patent/ZA200200738B/xx unknown
- 2002-02-15 NO NO20020770A patent/NO20020770L/no unknown

Also Published As

Publication number	Publication date
HK1046104A1 (zh)	2002-12-27
CN1370067A (zh)	2002-09-18
HUP0203601A2 (hu)	2003-02-28
TR200200376T2 (tr)	2002-06-21
KR20020025971A (ko)	2002-04-04
CA2377133A1 (en)	2001-02-22
EA200200117A1 (ru)	2002-06-27
EP1210080A2 (en)	2002-06-05
EP1078632A1 (en)	2001-02-28
EE200200062A (et)	2003-04-15
NO20020770D0 (no)	2002-02-15
AR025244A1 (es)	2002-11-13
NO20020770L (no)	2002-04-16
WO2001012176A3 (en)	2002-03-21
AU6441900A (en)	2001-03-13
WO2001012176A2 (en)	2001-02-22
IS6251A (is)	2002-01-25
IL147790A0 (en)	2002-08-14
MXPA02001649A (es)	2002-10-23
SK2162002A3 (en)	2002-07-02
CZ2002554A3 (cs)	2002-05-15
PL364865A1 (pl)	2004-12-27
JP2003506485A (ja)	2003-02-18
BR0013282A (pt)	2002-04-23

Publication	Publication Date	Title
ZA200200738B (en)	2003-03-26	Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity.
ZA200408772B (en)	2005-11-18	11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia.
ZA200109073B (en)	2003-01-29	Compositions for treatment of disorders of the oesophagus.
AU2003207717B9 (en)	2009-05-07	11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AU2003299791A1 (en)	2004-07-22	Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
PL366619A1 (en)	2005-02-07	Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
AU2003281978A1 (en)	2004-06-18	2,5-diketopiperazines for the treatment of obesity
AU2935200A (en)	2000-11-17	Compounds for the treatment of obesity
PL350412A1 (en)	2002-12-02	2−amino−benzoxazinone derivatives for the treatment of obesity
IL196301A0 (en)	2009-09-22	Medicament for the treatment of hapatitis c
MXPA02003665A (es)	2003-10-14	Derivados de heterociclos de 5 miembros, su preparacion y su uso como medicamentos.
PL362690A1 (en)	2004-11-02	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
ZA200500323B (en)	2006-02-22	Use of lkb kinase inhibitors for the treatment of pain.
AP2004002997A0 (en)	2004-03-31	Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract.
ZA200203443B (en)	2004-03-31	Medical bandaging product with tubular-knitted substrate.
HUP0301333A3 (en)	2005-06-28	Pharmaceutical superdisintegrant, process for its preparation and its use
AU2003290059A8 (en)	2004-07-09	Use of cd137 antagonists for the treatment of tumors
AU2003263760A1 (en)	2004-01-19	Methods for the treatment or prevention of obesity
ZA200003236B (en)	2002-01-02	Combination therapy for the treatment of migraine.
MXPA02012907A (es)	2003-09-22	Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
ZA200501288B (en)	2005-09-05	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
ZA200405173B (en)	2005-06-21	2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence.
HUP0001891A2 (en)	2001-03-28	Medicament for the treatment of migraine
AU2003266960A1 (en)	2004-06-30	Composition for the treatment of pain, especially for the treatment of articular pain
ZA200003235B (en)	2002-01-02	Combination therapy for the treatment of migraine.